It means that the committee can now accept evidence generated by the tool as scientifically valid in future applications and assessments for new MASH treatments. MASH is a condition linked with ...
This collaboration focuses on the development and commercialization of OliX’s OLX75016, a Phase 1 candidate primarily targeting metabolic-associated steatohepatitis (MASH) and other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback